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Summary
Aging is associated with impaired vaccine efficacy and increased
susceptibility to infectious and malignant diseases. CD8+ T-cells
are key players in the immune response against pathogens and
tumors. In aged mice, the dwindling na€ıve CD8+ T-cell compart-
ment is thought to compromise the induction of de novo immune
responses, but no experimental evidence is yet available in
humans. Here, we used an original in vitro assay based on an
accelerated dendritic cell coculture system in unfractioned
peripheral blood mononuclear cells to examine CD8+ T-cell
priming efficacy in human volunteers. Using this approach, we
report that old individuals consistently mount quantitatively and
qualitatively impaired de novo CD8+ T-cell responses specific for a
model antigen. Reduced CD8+ T-cell priming capacity in vitro was
further associated with poor primary immune responsiveness
in vivo. This immune deficit likely arises as a consequence of
intrinsic cellular defects and a reduction in the size of the na€ıve
CD8+ T-cell pool. Collectively, these findings provide new insights
into the cellular immune insufficiencies that accompany human
aging.
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Introduction
Elderly people suffer more often and more severely from infectious and
malignant diseases than young individuals. Responses to vaccination are
also less effective in the elderly. These manifestations are thought to
reflect an age-related functional decline in the immune system
(Dorshkind et al., 2009). An integrated understanding of the aging
immune system is therefore essential for the delivery of optimal
healthcare to the elderly population. Adaptive immunity mediated by
T-cells is critically important in the host response to various pathogens
and cells undergoing malignant transformation. However, increasing
evidence suggests that age-related changes limit the efficacy of cellular
immune responses against emerging strains of influenza virus and tumor
cells. Thus, while recall responses to pathogens encountered earlier in
life are largely uncompromised, primary T-cell-mediated immune
responses appear to decline with advanced age (Nikolich-Zugich, 2014).
Primary T-cell responses originate from the na€ıve T-cell compartment,
which provides a clonotypically diverse reservoir of specific precursors
that differentiate upon antigen engagement to populate the memory
and effector T-cell compartments (Stemberger et al., 2007). In turn, the
na€ıve T-cell pool is generated by thymic output. However, the thymus
atrophies with age, a process termed ‘thymic involution’ (Gruver et al.,
2007). This progressive decay in thymic function leads to a correspond-
ing loss of na€ıve T-cells and increased homeostatic proliferation within
the naive T-cell compartment (Kohler & Thiel, 2009; Sauce et al., 2012).
Nonetheless, such enhanced proliferation is insufficient to maintain the
number (Sauce et al., 2012) and clonotypic diversity (Naylor et al., 2005)
of peripheral na€ıve T-cells in elderly adults. Collectively, these observa-
tions indicate that the na€ıve T-cell pool becomes quantitatively impaired
with advanced age.
Recent studies in animal models further suggest qualitative alterations
in the na€ıve T-cell compartment and impaired induction of de novo T-cell
responses with age (Brien et al., 2009; Cicin-Sain et al., 2010; Smithey
et al., 2011; Renkema et al., 2014). Indeed, contraction of the murine
na€ıve T-cell repertoire can impair T-cell responses to immunodominant
epitopes (Yager et al., 2008; Valkenburg et al., 2012). Intrinsic age-
related defects in na€ıve T-cell responsiveness linked to gene expression
profiles and cytokine secretion have also been documented in old mice
(Mirza et al., 2011; Decman et al., 2012; Jiang et al., 2013). In contrast,
experimental evidence for compromised na€ıve T-cell responsiveness in
old humans is scarce (Goronzy & Weyand, 2013; Appay & Sauce, 2014).
This is an important knowledge gap given that differences have been
observed in age-associated na€ıve T-cell dynamics between mice and
humans (den Braber et al., 2012).
One recent study revealed an alteration in na€ıve CD4+ T-cell activation
and differentiation in the elderly, associated with a defect in TCR-
induced extracellular signal-regulated kinase (ERK) phosphorylation (Li
et al., 2012). Age-related changes in humans have also been described
for memory CD8+ T-cells, which provide frontline defence against viruses
and tumors (Appay et al., 2008). In particular, elderly individuals harbor
a higher proportion of terminally differentiated (CD28) memory CD8+
T-cells, which exhibit strong effector functions constrained by limited
proliferative capabilities in tandem with short telomeres (reviewed in
Pawelec et al., 1999). More recently, Akbar and colleagues have
provided new insights into the associated molecular defects (Henson
et al., 2014). However, there is limited information regarding the
capacity of old humans to mount primary CD8+ T-cell responses.
Evaluating de novo antigen-specific T-cell responses in humans is
difficult beyond the limited setting of vaccination and primary infection.
To overcome this difficulty, we developed an in vitro assay to assess
na€ıve CD8+ T-cell priming directly from unfractionated peripheral blood
mononuclear cells (PBMCs). This approach is based on an accelerated
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dendritic cell (DC) coculture system, designed for the optimal activation
of antigen-specific T-cells from PBMCs (Martinuzzi et al., 2011). As
circulating human DCs are rare, DC precursors within the starting PBMC
material were mobilized using FLT3 ligand (FLT3L) (Breton et al., 2015),
known for its capacity to enhance the induction of T-cell responses
(Guermonprez et al., 2013), and matured with a standard cocktail of
inflammatory cytokines (TNF, IL-1b, PGE2, and IL-7).Furthermore, we
focused on the priming of CD8+ T-cells specific for the melanoma
antigen Melan-A/MART-1, restricted by HLA-A*0201 (HLA-A2 from
hereon). This specificity is particularly amenable to in vitro studies with
limited volume blood samples due to naturally high precursor frequen-
cies in the naive pool and the widespread occurrrence of HLA-A2 in the
general population. Equipped with this original and broadly applicable
assay, we set out to obtain further insights into the decline of CD8+ T-cell
immunity with age.
Results
In vitro model of antigen-specific na€ıve CD8+ T-cell priming
The frequency of circulating antigen-reactive CD8+ T-cell precursors in
humans is typically very low, often in the order of one cell per million
within the lineage as a whole (Alanio et al., 2010; Legoux et al., 2010;
Iglesias et al., 2013). To circumvent this biological obstacle to the reliable
study of antigen-specific priming in vitro, we exploited the observation
that individuals expressing the HLA-A2 allotype harbor exceptionally high
frequencies of precursors (i.e., 10–100 na€ıve cells per million CD8+ T-
cells) specific for the heteroclitic Melan-A/MART-1 epitope ELAGIGILTV
(ELA from hereon) (Dutoit et al., 2002; Zippelius et al., 2002). This large
antigen-specific pool in the na€ıve CD8+ T-cell compartment provides a
unique means to study the priming of human T-cells that recognize ELA,
used here as a model antigen (Pinto et al., 2014; Romero et al., 2014). It
is also notable that the Melan-A/MART-1 epitope is an important
melanoma-associated antigen. Studying Melan-A/MART-1-specific T-cell
priming is therefore directly relevant to the assessment of antitumor
immunity in the elderly. Combined with the high frequency of the HLA-
A2 allotype in the Caucasian population (i.e., ~45% prevalence), this
approach enabled reproducible in vitro priming using a small number of
PBMCs (5 9 106 in our assays) from a large number of (HLA-A2+)
individuals, in response to stimulation with the cognate ELA epitope
encompassed within a longer (i.e., 20-mer) synthetic peptide.
Upon priming from total PBMCs with a stimulation cocktail incorpo-
rating the ELA peptide, FLT3L, TNF-a, IL-1b, PGE2, and IL-7 (Martinuzzi
et al., 2011), ELA-specific CD8+ T-cells were quantified by flow
cytometry using fluorochrome-labeled ELA/HLA-A2 tetramers (Fig. 1A),
and their differentiation phenotype was assessed according to CD45RA
and CCR7 surface expression (Fig. 1B). After expansion, the majority of
ELA-specific CD8+ T-cells exhibited a memory phenotype (CD45RA
CCR7+/), reflecting the differentiation of ELA-reactive na€ıve CD8+ T-cell
precursors (CD45RA+ CCR7+). No expansion of ELA-specific CD8+ T-cells
was observed priming in the absence of peptide (data not shown).
Although it is established that ELA-reactive CD8+ T-cells in healthy
donors can be defined as na€ıve T-cells (characterized by a CD45RA+
CCR7+ phenotype, a high TREC content and long telomeres) (Dutoit
et al., 2002; Zippelius et al., 2002), we confirmed that ELA-specific T-cell
priming in these donors was indeed occurring within the na€ıve (and not
memory) CD8+ T-cell compartment. For this purpose, we mixed purified
na€ıve or memory CD8+ T-cells separately with autologous CD8-depleted
PBMCs to initiate priming (Fig. 1C). Antigen-specific expansion was only
observed with na€ıve CD8+ T-cells (Fig. 1D), thereby validating the
experimental system. Optimization experiments with healthy donor
PBMC samples revealed maximal ELA-specific CD8+ T-cell expansion at
10–11 days postpriming (Fig. 1E). This time course was adopted in all
subsequent assays.
In vitro CD8+ T-cell priming as a correlate of de novo immune
responsiveness
Initially, we studied a group of HLA-A2+ elderly individuals who mounted
a primary immune response in vivo, upon vaccination for the first time
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Fig. 1 In vitro priming of antigen-specific CD8+ T-cells from na€ıve precursors. (A) Representative flow cytometry plots showing ELA/HLA-A2 tetramer staining of donor
PBMCs before (day 0) and after (day 10) priming. Percentages of ELA/HLA-A2 tetramer+ cells within the CD8+ T-cell population are indicated. (B) Representative phenotype
of ELA/HLA-A2 tetramer+ (black) or total (gray) CD8+ T-cells at day 0 and at day 10 postpriming. Percentages of ELA/HLA-A2 tetramer+ na€ıve CD8+ T-cells (CD45RA+ CCR7+)
are shown. (C) Representative flow cytometry plots showing the phenotypes of total, na€ıve, and memory purified CD8+ T-cells used for in vitro priming. Percentages of na€ıve
CD8+ T-cells (CD45RA+ CCR7+) are indicated. (D) Tetramer staining of ELA-specific CD8+ T-cells at day 10 postpriming is shown for each of the starting populations depicted
in (C). Purified na€ıve and memory CD8+ T-cell populations were supplemented separately with autologous CD8-depleted PBMCs to initiate priming. Percentages of ELA/HLA-
A2 tetramer+ cells within the CD8+ T-cell population are indicated. Data shown are representative of three independent experiments. (E) Expansion kinetics of ELA/HLA-A2
tetramer+ CD8+ T-cells after antigen-specific priming of PBMCs from 10 different healthy donors.
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against tick-borne encephalitis virus (TBEv). The individuals selected for
this study had never been exposed to TBEv as indicated by the absence
of serum anti-TBEv antibodies prior to vaccination. De novo humoral and
cellular immune responses to TBE vaccination were monitored at weeks
8 and 28 or at week 26 postimmunization, respectively, and compared
to baseline values. Among forty HLA-A2+ vaccinees, we could define
good (n = 12) and poor (n = 12) TBE vaccine responders, referring to
donors with both TBEv binding and neutralizing antibody levels at weeks
8 or 28 postimmunization within the top and bottom quartiles of all titer
values, respectively (Fig. 2A). Assessment of CD8+ T-cell priming efficacy
was performed in these individuals using our in vitro approach. Good
TBE vaccine responders displayed significantly stronger CD8+ T-cell
priming efficacies in vitro compared to poor responders (Fig. 2B).
Moreover, the frequency of ELA/HLA-A2 tetramer+ cells after in vitro
expansion assessed at day 0 (i.e., prevaccination) was associated with
subsequent TBE vaccine responsiveness: high primers with ELA/HLA-A2
tetramer+ cell expansions above the median frequency (i.e., 0.28% of
tetramer+ cells within CD8+ T lymphocytes) at day 0 constituted a
significantly greater proportion of good TBE vaccine responders
compared to low primers (Fig. 2C). In addition, we found a direct
correlation between in vitro CD8+ T-cell priming capacity at day 0 and
ex vivo TBE cellular responses measured at week 26 postimmunization in
vaccinees who displayed a detectable TBE cellular response (n = 14)
(Fig. 2D). Overall, although the mechanistic tie between responsiveness
to a model antigen in vitro and to a vaccine in vivo is most likely indirect,
these data indicate that the impairment of CD8+ T-cell priming efficacy
as measured in vitro in our assay reflects to some extent in vivo immune
defects.
Quantitative reduction of CD8+ T-cell priming efficacy in the
elderly
The magnitude of ELA/HLA-A2 tetramer+ cells after in vitro expansion
was used to compare antigen-specific CD8+ T-cell priming capacity in
HLA-A2+ healthy middle-aged and elderly (>70 years old) adults. Using
this approach, we found that the expansion of CD8+ T-cells specific for
our model antigen was significantly lower in elderly individuals compared
to middle-aged controls (Fig. 3A). This finding implies that advanced age
is associated with quantitatively impaired CD8+ T-cell priming. Recent
studies in murine models suggest that the frequency of na€ıve T-cell
precursors correlates with the magnitude of the primary T-cell response
(Moon et al., 2007; Kotturi et al., 2008; Obar et al., 2008). Accordingly,
we quantified na€ıve ELA-specific CD8+ T-cell precursor frequencies in a
subset of healthy donors using an established procedure for the
enrichment of CD45RA+ CCR7+ tetramer+ cells from PBMC samples
via magnetic separation (Fig. 3B) (Alanio et al., 2010). A direct corre-
lation was observed between the frequency of ELA/HLA-A2 tetramer+
cells after in vitro expansion and the frequency of ELA-specific CD8+ T-
cell precursors (Fig. 3C). Due to the high number of PBMCs required for
antigen-specific precursor quantification, the same approach was not
possible in elderly individuals. Instead, we measured the frequency of
total na€ıve (CD45RA+ CCR7+ CD27+) CD8+ T-cells in these donors. A
direct correlation was observed between the frequency of primed ELA/
HLA-A2 tetramer+ cells and the frequency of na€ıve CD8+ T-cells in this
group (Fig. 3D). Overall, these data support a relationship between the
size of the na€ıve T-cell pool and the efficacy of CD8+ T-cell priming in
humans. Accordingly, impaired CD8+ T-cell priming in the elderly may be
attributed, at least in part, to declining thymic output and a consequent
reduction in na€ıve T-cell frequencies.
In donors with large expansions of ELA-specific CD8+ T-cells after
in vitro priming (i.e., > 0.4% ELA/HLA-A2 tetramer+ CD8+ T-cells), we
also performed parallel experiments using CD8-null ELA/HLA-A2
tetramers (Fig. 3E). These reagents incorporate the compound D227K/
T228A mutation into the a3 domain of the HLA-A2 heavy chain, which
abrogates CD8 coreceptor binding, thereby enabling the selective
identification of high-avidity antigen-specific CD8+ T-cells (Price et al.,
2005; Wooldridge et al., 2009). High-avidity CD8+ T-cells are known to
display superior functional (e.g., cytolytic and polyfunctional) attributes
and greater efficacy against pathogens and tumors (Appay et al., 2008).
In line with the results obtained using standard tetramers, significantly
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Fig. 2 Assessment of in vitro CD8+ T-cell priming capacity in elderly adults. (A)
Binding and neutralizing antibody titers specific for TBEv in elderly (>70 years old)
adults before and at weeks 8 and 28 after the first immunization. Top and bottom
quartiles of titer values (indicated by the upper and lower frames respectively) at
weeks 8 or 28 were used to define good (n = 12) and poor (n = 12) TBE vaccine
responders, respectively. (B) Frequencies of ELA/HLA-A2 tetramer+ CD8+ T-cells
after in vitro priming in good or poor TBE vaccine responders. Bars indicate median
values. The statistical comparison was conducted using the Mann–Whitney U-test.
(C) Association between in vitro CD8+ T-cell priming efficacy prior to TBE
vaccination and TBE vaccine responsiveness based on anti-TBEv antibody titers.
Statistical significance was assessed using the chi-square test. (D) Correlation
between in vitro CD8+ T-cell priming efficacy prior to TBE vaccination and the de
novo TBE-specific T-cell responses determined by IFN-c ELISpot at week 26
postimmunization. The correlation was determined using Spearman’s rank test.
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lower frequencies of primed CD8-null ELA/HLA-A2 tetramer+ CD8+ T-
cells were observed in elderly individuals compared to middle-aged
controls (Fig. 3F). Importantly, the CD8-null/standard tetramer frequency
ratios (i.e., the proportion of high-avidity T-cells among primed
lymphocytes) were also lower in the elderly group (Fig. 3G). Thus,
advanced age is associated with lower frequencies of avidity-impaired
primary responses, presumably as a result of repertoire perturbations
within the na€ıve CD8+ T-cell pool associated with a reduction in na€ıve T-
cell frequencies.
Altered quality of in vitro primed CD8+ T-cells originating
from elderly individuals
Next, we used our approach to assess qualitative features of antigen-
specific CD8+ T-cells primed in vitro, comparing samples from healthy
middle-aged and elderly donors. Although the majority of ELA-specific
CD8+ T-cells primed from middle-aged adult samples displayed a
CD45RA CCR7 effector memory phenotype, expanded ELA/HLA-A2
tetramer+ cells from elderly donor PBMCs were typically CD45RA
CCR7+, a phenotype usually associated with less differentiated cells
(Fig. 4A). This observation suggests less efficient activation of elderly
na€ıve CD8+ T-cells, and altered differentiation into effector memory cells,
potentially due to qualitative cellular defects. Impaired CD8+ T-cell
priming may also be related to intrinsic defects in old na€ıve T-cells and
failure to expand in response to TCR-mediated signals. We therefore
tested the capacity of total na€ıve (CD45RA+ CCR7+ CD27+) CD8+ T-cells
from elderly or middle-aged control PBMC samples to proliferate upon
anti-CD3/CD28 stimulation. Elderly na€ıve CD8+ T-cells displayed a
reduction in proliferative capacity, as illustrated by lower Cell Prolifer-
ation Dye (CPD) dilution 4 days after stimulation (Fig. 4B, C).
In addition, we assessed rapid phosphorylation of ERK upon anti-CD3/
CD28 stimulation. ERK is a central element of the TCR signaling complex,
with phosphorylation resulting in the induction of AP-1, an essential
transcription factor required for optimal T-cell activation and prolifera-
tion. Upon stimulation, ERK phosphorylation was weaker in elderly na€ıve
CD8+ T-cells compared to middle-aged donor controls (Fig. 4D),
suggesting impaired TCR signaling in these cells. We next analyzed the
intracellular expression in primed CD8+ T-cells of the T-box transcription
factor T-bet (also known as Tbx-21), which lies further downstream in
the TCR signaling pathway and plays an important role in effector
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Fig. 3 Assessment of qualitative attributes
of CD8+ T-cells primed in vitro. (A)
Frequencies of ELA/HLA-A2 tetramer+
CD8+ T-cells after in vitro priming (day 10)
in healthy, HLA-A2+ middle-aged (n = 20,
Mid) and elderly (>70 years old) adults
(n = 46, Old). (B) Representative flow
cytometry plots showing ELA-specific CD8+
T-cell precursors in a healthy donor before
and after enrichment from 108 PBMCs.
Percentages of ELA/HLA-A2 tetramer+ cells
within the CD8+ T-cell population are
indicated. (C) Correlation between ELA-
specific CD8+ T-cell precursor (CD45RA+
CCR7+) frequency and ELA/HLA-A2
tetramer+ CD8+ T-cell frequency after
in vitro priming in middle-aged healthy
adults (n = 20). (D) Correlation between
na€ıve CD8+ T-cell frequency and ELA/HLA-
A2 tetramer+ CD8+ T-cell frequency after
in vitro priming in healthy elderly (>70 years
old) adults. Correlations were determined
using Spearman’s rank test. (E)
Representative flow cytometry plots
showing standard or CD8-null tetramer
staining to identify total or high-avidity ELA-
specific CD8+ T-cells, respectively.
Percentages of ELA/HLA-A2 tetramer+ cells
within the CD8+ T-cell population are
indicated. (F) Frequencies of high-avidity
ELA-specific CD8+ T-cells in healthy middle-
aged (n = 17) and elderly (n = 19) adults
with strong expansions (>0.4%) of total
ELA/HLA-A2 tetramer+ CD8+ T-cells after
in vitro priming. (G) CD8-null/standard
ratios for ELA/HLA-A2 tetramer+ CD8+ T-
cells in healthy middle-aged (n = 17) and
elderly (n = 19) adults after in vitro priming.
Bars indicate median values. Statistical
analyses were conducted using the Mann–
Whitney U-test.
T-cell priming and immunosenescence, O. Brice~no et al. 17
ª 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
memory T-cell differentiation (Glimcher et al., 2004). ELA-specific CD8+
T-cells expanded from elderly donor PBMCs exhibited significantly less T-
bet expression compared to CD8+ T-cells primed from middle-aged adult
samples (Fig. 4E), further supporting the notion of altered TCR signaling
in older individuals. In CD8+ T-cells, T-bet is a master regulator of the
expression of effector molecules such as granzyme B and perforin. In line
with their low T-bet expression, CD8+ T-cells primed from elderly donor
PBMCs also displayed a significant reduction in granzyme B and perforin
content compared to middle-aged donor controls (Fig. 4F).
Overall, a quantitative shrinkage of the na€ıve T-cell pool, together
with qualitative defects in old na€ıve CD8+ T lymphocytes, exemplified by
impaired TCR signaling and poor proliferative capacity, is likely to result
in the generation of fewer and mostly paucifunctional effector CD8+
T-cells. Together, these factors may contribute to a reduction in CD8+
T-cell priming efficacy in the elderly.
Discussion
Although studies performed in animal models point to a decline in the
inductionofdenovoCD8+ T-cell responseswithold age, no corresponding
human data are available. This is largely due to a lack of practical assays
designed to assess priming capacity in humans. To overcome these
limitations, we developed a simple and original in vitro approach to assess
the efficacy of antigen-specific T-cell priming directly from human blood
samples. We focused our study on na€ıve CD8+ T-cell responses to the
immunodominant melanoma antigen Melan-A/MART-1, which is
restricted by the HLA-A2 molecule. The highly immunogenic heteroclitic
variant of Melan-A/MART-1, ELA, was used as a model antigen. Starting
from donor PBMCs, the assay relates in vitro priming capacity to the
induction of de novo immune responses in vivo; it thus represents a unique
setting to compare T-cell priming efficacy between HLA-matched individ-
uals. Using this approach,we found that elderly adults displayed a reduced
ability to prime antigen-specific CD8+ T-cells. More importantly, however,
the quality of these primed T-cells was altered. On one hand, the induction
of high-avidity CD8+ T-cells appeared to be particularly affected in the
elderly. This is in line with a recent report describing higher proportions of
low-avidity virus-specific memory CD8+ T-cells in old individuals (Griffiths
et al., 2013). On the other hand, primed CD8+ T-cells derived from elderly
donor samples displayed significantly lower levels of the cytotoxins
perforin and granzyme B. Taking into account the importance of TCR
avidity and cytolytic functions for CD8+ T-cell efficacy (Appay et al., 2008),
declining numbers of high-quality T-cells represent a particular drawback
for cellular immune competence.
Multiple parameters determine the fate of T-cells upon priming with
antigen. Studies performed in mice have shown that the na€ıve T-cell
precursor frequency can greatly influence the induction of an effective T-
cell response (Moonet al., 2007;Kotturi et al., 2008;Obaret al., 2008). In
line with these findings, we demonstrated that the ex vivo precursor
frequency correlates with the magnitude of the in vitro primary T-cell
response. Furthermore, we observed a direct association between CD8+
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Fig. 4 Quantitative and qualitative analysis of the na€ıve CD8+ T-cell compartment. (A) Phenotypic distribution (based on CD45RA and CCR7 expression) of ELA/HLA-A2
tetramer+ CD8+ T-cells at day 10 postpriming in healthy middle-aged and elderly adults. (B) Representative flow cytometry histograms showing CPD dilution in na€ıve (gated
on CD45RA+ CCR7+ CD27+) CD8+ T-cells from middle-aged and elderly adults 4 days after stimulation with anti-CD3/CD28 beads (in white) or medium alone (in black). (C)
Percentages of CPD-low na€ıve CD8+ T-cells from middle-aged and elderly adults 4 days after stimulation with anti-CD3/CD28 beads. (D) Phosphorylation of ERK in na€ıve
CD8+ T-cells, from middle-aged and elderly adults expressed as the MFI ratio under conditions of anti-CD3/CD28 stimulation versus medium alone. (E) Intracellular T-bet
expression by ELA-specific CD8+ T-cells at day 10 postpriming from healthy middle-aged adult and elderly PBMC samples. (F) Granzyme B and perforin expression by ELA-
specific CD8+ T-cells at day 10 postpriming from healthy middle-aged adult and elderly PBMC samples. Bars indicate median values. Statistical comparisons were conducted
using the Mann–Whitney U-test.
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T-cell priming efficacy and the size of the na€ıve T-cell pool in elderly
individuals. This finding suggests that compromised CD8+ T-cell priming
efficacy in elderly individuals is related to a decrease in the size of the na€ıve
CD8+ T-cell compartment and associated repertoire perturbations. One
study suggested that the diversity of the na€ıve CD4+ TCR repertoire is
maintained throughout adulthood but then undergoes a precipitous
decline beyond 70 years of age (Naylor et al., 2005). Due to the low
frequency of na€ıve cells possessing high-avidity TCRs (at least with respect
to ELA specificity), the recruitment of effective clonotypes may be
particularly affected by the restricted na€ıve T-cell repertoire in old age.
Thymic involution, dwindling thymic output and new na€ıve T-cell
production (Gruver et al., 2007), which all accompany aging, therefore
likely play an important role in the loss of T-cell priming efficacy observed
with age.
Other causes of reduced CD8+ T-cell priming efficacy also need to be
considered, including intrinsic qualitative cellular defects, which may
affect the activation and differentiation of primed CD8+ T-cells in the
elderly. For instance, our data indicate that old individuals exhibit
impaired TCR signaling, associated with suboptimal proliferation of na€ıve
CD8+ T-cells. Potential defects in TCR signaling, as indicated by reduced
ERK phosphorylation in na€ıve CD8+ T-cells and lower T-bet expression in
primed cells, may account for less efficient activation of elderly na€ıve
CD8+ T-cells. Cellular processes such as differentiation into effector
memory cells may consequently be altered, leading to the generation of
T-cells with limited functional properties, as we observed after in vitro
priming. These qualitative cellular defects are reminiscent of observations
from an aged mouse model of infection (Smithey et al., 2011). Our data
are also consistent with recent findings by Li et al., who characterized an
age-related defect in TCR-induced ERK phosphorylation and antigen
sensitivity in old na€ıve human CD4+ T-cells (Li et al., 2012). In this study,
the defect in ERK phosphorylation was associated with reduced
expression of miR-181a in na€ıve CD4+ T-cells with old age, resulting in
increased DUSP6 activity and, ultimately, desensitization of the TCR
cascade. It is unclear at present whether a similar mechanism is at work
in old na€ıve CD8+ T-cells. Furthermore, it remains to be determined
whether the increased nonspecific homeostatic proliferation that char-
acterizes na€ıve T-cells in the elderly influences priming efficacy upon
antigen encounter, potentially via effects on cellular metabolism and the
acquisition of functional properties (Sauce et al., 2012).
The signals delivered to na€ıve T-cells upon priming depend further on
the nature of the antigen-presenting cell. Increasing evidence suggests
that the capacity of DCs to capture and process antigen is compromised
with old age (Gupta, 2014). Other age-related changes affecting DCs,
for instance at the level of costimulatory protein expression and the
speed of response to stress molecules (e.g., Toll-like receptor ligands),
were also highlighted in a recent report (Metcalf et al., 2014). In this
study, the defective response to innate immune agonists (e.g., TLR4,
TLR7/8, and RIG-I ligands) resulted in reduced production of pro-
inflammatory cytokines and chemokines (e.g., TNF-a, IL-6, IL-1b, IFN-a,
IFN-c, CCL2, and CCL7), contributing to impaired T-cell proliferation.
Given the importance of DCs in the process of T-cell priming, these
observations imply that perturbations of the DC compartment may also
contribute to altered CD8+ T-cell priming capacity. Reduced T-cell
priming efficacy with old age may therefore be related to the loss of
primary immune resources, combining alterations in both na€ıve T-cell
and DC frequency and function. As our present approach does not allow
us to fully discriminate between the different factors affecting T-cell
priming efficacy, further studies are needed to decipher the precise
mechanisms involved. In addition, as the present study focused on the
priming of CD8+ T-cells specific for the Melan-A/MART-1- model
antigen, it will be important to extend our observations to other
specificities. Our in vitro approach offers the potential to study
responses directed against other epitopes and different HLA restrictions.
However, given the in vitro nature of these observations and the
contingent necessity to interpret them with caution, the altered quality
of de novo T-cell responses in the elderly will need to be confirmed
directly in vivo.
The decline of immune competence with advanced age emerges as a
global phenomenon, with parallel alterations to the cellular, humoral,
and innate arms of the immune system. In this context, the present work
provides evidence of impaired de novo CD8+ T-cell responses in elderly
individuals. We propose that this phenomenon contributes to the loss of
vaccine responsiveness and immune protection against pathogens and
tumors in old humans.
Experimental procedures
Study subjects and samples
Two groups of HLA-A2+ Caucasian volunteers were enrolled in this
study: (i) middle-aged (20 < age < 50) healthy adults (median age,
35 years); and (ii) elderly (>70 years old) healthy adults (median age,
78 years). Volunteers were screened for surface HLA-A2 expression by
flow cytometry using anti-HLA-A2 antibodies (BD Biosciences, San
Diego, CA). Individuals undergoing immunosuppressive therapy were
excluded from the study. Among the elderly, we studied an additional
group of individuals who received a full TBE immunization course of
three injections at weeks 0, 4, and 24 with a licensed inactivated whole
virus vaccine (FSME Immun; Baxter, Volketswil, Switzerland) as part of a
clinical trial (NCT00461695). All individuals were healthy (no chronic
diseases, ≤ one medication) and seronegative for TBEv. Assays of
immune reactivity were conducted prior to vaccination, and at weeks 8
and 28 postvaccination for humoral and at week 26 for cellular
responses. The study was approved by the Comite de Protection des
Personnes of the Pitie Salpetriere Hospital (Paris) and by the Cantonal
Ethics Committe (Zurich). All participants provided written informed
consent. Venous blood samples were drawn into anticoagulant tubes,
and PBMCs were isolated by density gradient centrifugation according to
standard protocols.
In vitro priming of antigen-specific CD8+ T-cell precursors
Na€ıve precursors specific for the HLA-A2-restricted epitope ELAGIGILTV
(ELA) were primed in vitro using a previously published method with
minor adaptations (Martinuzzi et al., 2011). Briefly, thawed PBMCs were
resuspended in AIM medium (Invitrogen, Carlsbad, CA), plated out at
2.5 9 106 cells/well in a 48-well tissue culture plate, and stimulated with
the peptide YTAAEELAGIGILTVILGVL, which contains the optimal
epitope in heteroclitic form, at a concentration of 1 lM in the presence
of FLT3 ligand (50 ng mL1; R&D Systems, Minneapolis, MN). After 24 h
(day 1), maturation was induced by the addition of a cytokine cocktail
comprising TNF-a (1000 U mL1), IL-1b (10 ng mL1), IL-7
(0.5 ng mL1), and PGE2 (1 lM) (R&D Systems) (Martinuzzi et al.,
2011). On day 2, fetal calf serum (FCS; Gibco, Carlsbad, CA) was added
to reach 10% by volume per well. Fresh RPMI-1640 (Gibco) enriched
with 10% FCS was subsequently used to replace the medium every
3 days. The frequency and phenotype of ELA-specific CD8+ T-cells were
typically determined on day 10. Purified na€ıve and memory CD8+ T-cell
subsets for priming experiments were obtained using T-cell Enrichment
Column Kits (R&D Systems).
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Flow cytometry reagents and procedures
Fluorochrome-conjugated ELA/HLA-A2 tetramers were produced and
used as described previously (Price et al., 2005). The D227K/T228A
compound mutation was introduced into the a3 domain of HLA-A2 to
generate CD8-null tetramers, which enable the selective identification of
high-avidity antigen-specific CD8+ T-cells (Purbhoo et al., 2001;
Wooldridge et al., 2009). The following directly conjugated monoclonal
antibodies were used according to standard protocols: aCD8 APC-Cy7
(Caltag, Carlsbad, CA); aCD27 AlexaFluor 700 (BioLegend San Diego,
CA); aCD45RA ECD (Beckman Coulter, Miami, FL); a-perforin-BD48 FITC
(Abcam, Cambridge, MA); a-T-bet AlexaFluor647 (eBiosciences, San
Diego, CA); and aCCR7 PE-Cy7, aHLADR PE-CF594, aCD11c V450,
aCD123 PE-Cy7, a-granzyme B V450, and lineage cocktail (including
aCD3, aCD14, aCD16, aCD19, aCD20, aCD56) FITC (BD Biosciences).
Samples were acquired using a Fortessa flow cytometer (BD Biosciences).
Intracellular staining for T-bet was performed using the Transcription
Factor Buffer Set (BD Pharmingen, San Diego, CA) according to the
manufacturer’s instructions. Intracellular staining for granzyme B and
perforin-BD48 was compatible with this procedure. Data analysis was
conducted with FACSDIVA 7.0 (BD Biosciences) and FLOWJO v9 (TreeStar Inc.)
software. Ex vivo frequencies of ELA-specific precursors were determined
from pre-enriched PBMC samples according to published procedures
(Alanio et al., 2010; Iglesias et al., 2013).
Analysis of TBEv-specific humoral and cellular immune
responses
TBEv-specific antibody titers were measured before (week 0), during
(week 8), and after (week 28) the TBEv vaccination course by ELISA and
TBEv-neutralization according to published protocols (Stiasny et al.,
2012). The TBEv-specific cellular immune response was assessed at
weeks 0 and 26 by IFN-c enzyme-linked immunosorbent spot (ELISpot)
assay using pools of overlapping peptides for all structural proteins of
TBEv. Briefly, 2 9 105 thawed PBMCs/well from the same donor at week
0 and week 26 were stimulated in a-IFN-c (clone 1-D1K; Mabtech,
Nacka Strand, Sweden)-coated 96-well ELISpot plates (MAIP S45;
Millipore) for 18 h with 2 9 104 freshly generated autologous mono-
cyte-derived DCs. For antigen-specific stimulation, five pools of overlap-
ping peptides encompassing all structural proteins of TBEv were used at
a final concentration of 1lg mL1 (15-mer peptides overlapping by 5
amino acids; BMC Microcollections, Germany). Washed plates were then
incubated with a-IFN-c-biotin (7-B6-1; Mabtech) followed by strepta-
vidin–alkaline phosphatase (Mabtech), developed with color reagents
(170-6432; Bio-Rad , Marnes-la-Coquette, France) and analyzed in an
automated ELISpot reader (AID). The number of spot-forming units (SFU)
was calculated after subtraction of the unstimulated control.
Proliferation assay and ERK phosphorylation
Total PBMCs were stained with Cell Proliferation Dye eFluor 450 (CPD;
Affymetrix, eBiosciences) at 20 lM for 10 min, then washed and
stimulated with Dynabeads Human T-Activator CD3/CD28 (Life Tech-
nologies, Carlsbad, CA). Three days later, the percentage of CPD-low
cells was evaluated within na€ıve (CD45RA+ CCR7+ CD27+) CD8+ T-cells
by flow cytometry. To assess ERK1 and ERK2 phosphorylation, PBMCs
were stained with T-cell differentiation surface markers for 15 min at
room temperature and then exposed to Dynabeads Human T-Activator
CD3/CD28 (Life Technologies) for 2 min at 37°C. Cells were subse-
quently washed and fixed in BD Cytofix Fixation Buffer (BD Biosciences)
for 10 min at 37°C and then permeabilized with BD PhosflowTM Perm
Buffer III (BD Biosciences) for 20 min at 4°C. After washing, cells were
stained intracellularly for 1 h at room temperature using BD PhosflowTM
anti-human ERK1/2 conjugated to AlexaFluor647 (BD Biosciences) and
analyzed by flow cytometry.
Statistical analysis
Univariate statistical analyses were performed using GRAPHPAD PRISM
software. Groups were compared using the nonparametric Mann–
Whitney or chi-square tests. Spearman’s rank test was used to determine
correlations. P values below 0.05 were considered significant.
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